AMRX logo

Amneal Pharmaceuticals, Inc. (AMRX) Cash From Operations

Annual CFO:

$295.03M+$111.87M(+61.07%)
December 31, 2024

Summary

  • As of today, AMRX annual cash from operations is $295.03 million, with the most recent change of +$111.87 million (+61.07%) on December 31, 2024.
  • During the last 3 years, AMRX annual cash from operations has risen by +$53.21 million (+22.00%).
  • AMRX annual cash from operations is now -22.16% below its all-time high of $379.00 million, reached on December 31, 2020.

Performance

AMRX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

Quarterly CFO:

$83.82M+$76.41M(+1031.47%)
June 30, 2025

Summary

  • As of today, AMRX quarterly cash from operations is $83.82 million, with the most recent change of +$76.41 million (+1031.47%) on June 30, 2025.
  • Over the past year, AMRX quarterly cash from operations has increased by +$44.16 million (+111.36%).
  • AMRX quarterly cash from operations is now -67.72% below its all-time high of $259.65 million, reached on December 31, 2018.

Performance

AMRX Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

TTM CFO:

$351.01M+$44.16M(+14.39%)
June 30, 2025

Summary

  • As of today, AMRX TTM cash from operations is $351.01 million, with the most recent change of +$44.16 million (+14.39%) on June 30, 2025.
  • Over the past year, AMRX TTM cash from operations has increased by +$260.97 million (+289.83%).
  • AMRX TTM cash from operations is now -26.58% below its all-time high of $478.10 million, reached on March 31, 2021.

Performance

AMRX TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAMRXcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

AMRX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+61.1%+111.4%+289.8%
3Y3 Years+22.0%+202.8%+149.9%
5Y5 Years+10000.0%-53.2%+58.0%

AMRX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+365.1%-40.9%+421.8%at high+799.1%
5Y5-Year-22.2%>+9999.0%-43.4%+202.8%-26.6%+799.1%
All-TimeAll-Time-22.2%+1634.8%-67.7%+177.3%-26.6%+1376.3%

AMRX Cash From Operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$83.82M(+1031.5%)
$351.01M(+14.4%)
Mar 2025
-
$7.41M(-93.7%)
$306.85M(+4.0%)
Dec 2024
$295.03M(+61.1%)
$118.01M(-16.8%)
$295.03M(+95.4%)
Sep 2024
-
$141.77M(+257.5%)
$150.97M(+67.7%)
Jun 2024
-
$39.66M(+999.3%)
$90.04M(+130.6%)
Mar 2024
-
-$4.41M(+83.1%)
$39.04M(-78.7%)
Dec 2023
$183.16M(+188.7%)
-$26.05M(-132.2%)
$183.16M(-1.5%)
Sep 2023
-
$80.84M(+812.6%)
$185.92M(-6.4%)
Jun 2023
-
-$11.35M(-108.1%)
$198.65M(+54.6%)
Mar 2023
-
$139.71M(+699.8%)
$128.47M(+97.3%)
Dec 2022
$63.44M(-73.8%)
-$23.29M(-124.9%)
$65.10M(-57.1%)
Sep 2022
-
$93.57M(+214.8%)
$151.65M(+8.0%)
Jun 2022
-
-$81.52M(-206.8%)
$140.45M(-17.4%)
Mar 2022
-
$76.34M(+20.7%)
$170.04M(-29.7%)
Dec 2021
$241.82M(-36.2%)
$63.26M(-23.2%)
$241.82M(-15.0%)
Sep 2021
-
$82.36M(+258.6%)
$284.52M(+15.2%)
Jun 2021
-
-$51.93M(-135.1%)
$246.93M(-48.4%)
Mar 2021
-
$148.13M(+39.8%)
$478.10M(+26.1%)
Dec 2020
$379.00M(>+9900.0%)
$105.96M(+136.6%)
$379.00M(+70.6%)
Sep 2020
-
$44.78M(-75.0%)
$222.15M(-30.0%)
Jun 2020
-
$179.24M(+265.6%)
$317.29M(+99.4%)
Mar 2020
-
$49.03M(+196.3%)
$159.14M(+9233.8%)
Dec 2019
$1.71M(-99.3%)
-$50.89M(-136.4%)
$1.71M(-99.5%)
Sep 2019
-
$139.91M(+563.3%)
$312.25M(+33.2%)
Jun 2019
-
$21.09M(+119.5%)
$234.46M(+104.3%)
Mar 2019
-
-$108.41M(-141.8%)
$114.79M(-54.1%)
Dec 2018
$250.23M(+6.9%)
$259.65M(+317.9%)
$250.23M(+311.1%)
Sep 2018
-
$62.13M(+163.0%)
$60.87M(-9.5%)
Jun 2018
-
-$98.58M(-464.7%)
$67.23M(-59.5%)
Mar 2018
-
$27.03M(-61.5%)
$165.81M(+19.5%)
Dec 2017
$234.19M(+213.9%)
$70.29M(+2.6%)
$138.78M(+206.2%)
Sep 2017
-
$68.49M(+395.6%)
$45.32M(-39.3%)
Dec 2016
$74.60M(+3.7%)
-
-
Dec 2016
-
-$23.17M(-131.3%)
$74.60M(-44.6%)
Sep 2016
-
$73.98M(+237.8%)
$134.62M(+4.9%)
Jun 2016
-
-$53.67M(-169.3%)
$128.29M(+2.0%)
Mar 2016
-
$77.46M(+110.2%)
$125.73M(+74.8%)
Dec 2015
$71.93M(+119.2%)
$36.85M(-45.5%)
$71.93M(+415.5%)
Sep 2015
-
$67.66M(+220.3%)
$13.95M(+214.5%)
Jun 2015
-
-$56.24M(-337.7%)
-$12.19M(-116.6%)
Mar 2015
-
$23.66M(+212.0%)
$73.55M(+124.1%)
Dec 2014
$32.82M(-78.1%)
-$21.12M(-150.9%)
$32.82M(-32.5%)
Sep 2014
-
$41.52M(+40.8%)
$48.61M(+900.2%)
Jun 2014
-
$29.50M(+272.7%)
-$6.08M(-108.1%)
Mar 2014
-
-$17.08M(-220.6%)
$75.12M(-49.9%)
Dec 2013
$149.94M
-$5.33M(+59.6%)
$149.94M(+31.3%)
Sep 2013
-
-$13.17M(-111.9%)
$114.19M(-41.5%)
Jun 2013
-
$110.69M(+91.7%)
$195.31M(+39.3%)
DateAnnualQuarterlyTTM
Mar 2013
-
$57.75M(+240.6%)
$140.23M(+32.0%)
Dec 2012
$106.21M(+1570.5%)
-$41.08M(-160.4%)
$106.21M(-25.8%)
Sep 2012
-
$67.96M(+22.2%)
$143.19M(+41.9%)
Jun 2012
-
$55.60M(+134.3%)
$100.93M(+247.1%)
Mar 2012
-
$23.73M(+679.3%)
$29.08M(+357.3%)
Dec 2011
$6.36M(-97.5%)
-$4.10M(-115.9%)
$6.36M(+1826.7%)
Sep 2011
-
$25.70M(+258.1%)
$330.00K(-94.8%)
Jun 2011
-
-$16.25M(-1707.7%)
$6.40M(-97.0%)
Mar 2011
-
$1.01M(+110.0%)
$213.16M(-14.7%)
Dec 2010
$249.76M(+3161.9%)
-$10.12M(-131.9%)
$249.76M(-1.7%)
Sep 2010
-
$31.77M(-83.3%)
$254.09M(+14.4%)
Jun 2010
-
$190.50M(+406.5%)
$222.02M(+367.0%)
Mar 2010
-
$37.61M(+749.6%)
$47.54M(+682.8%)
Dec 2009
-$8.16M(-112.6%)
-$5.79M(-1779.9%)
-$8.16M(-120.0%)
Sep 2009
-
-$308.00K(-101.9%)
$40.78M(+16.3%)
Jun 2009
-
$16.02M(+188.6%)
$35.08M(+84.1%)
Mar 2009
-
-$18.08M(-141.9%)
$19.06M(-48.7%)
Dec 2008
$64.56M(-45.8%)
$43.15M(+818.0%)
$37.14M(+718.0%)
Sep 2008
-
-$6.01M(+6.2%)
-$6.01M(+78.1%)
Dec 2007
$119.01M(+2166.2%)
-
-
Dec 2006
-$5.76M(-127.2%)
-
-
Dec 2005
$21.15M(+210.0%)
-
-
Sep 2004
-
-$6.41M(+61.6%)
-$27.50M(-20.9%)
Jun 2004
-
-$16.68M(-434.8%)
-$22.75M(-70.2%)
Mar 2004
-
$4.98M(+153.0%)
-$13.37M(+30.4%)
Dec 2003
-$19.22M(-26.5%)
-$9.40M(-466.9%)
-$19.22M(-15.2%)
Sep 2003
-
-$1.66M(+77.3%)
-$16.68M(-10.4%)
Jun 2003
-
-$7.29M(-737.4%)
-$15.11M(-16.7%)
Mar 2003
-
-$871.00K(+87.3%)
-$12.95M(+14.8%)
Dec 2002
-$15.20M(+15.0%)
-$6.86M(-7606.7%)
-$15.20M(-18.7%)
Sep 2002
-
-$89.00K(+98.3%)
-$12.81M(+23.2%)
Jun 2002
-
-$5.13M(-64.0%)
-$16.68M(-1.2%)
Mar 2002
-
-$3.13M(+30.0%)
-$16.48M(+7.8%)
Dec 2001
-$17.88M(-11.7%)
-$4.47M(-12.8%)
-$17.88M(-4.9%)
Sep 2001
-
-$3.96M(+19.6%)
-$17.03M(+1.4%)
Jun 2001
-
-$4.92M(-8.8%)
-$17.28M(+3.6%)
Mar 2001
-
-$4.53M(-24.9%)
-$17.92M(-12.0%)
Dec 2000
-$16.00M(-137.6%)
-$3.62M(+13.9%)
-$16.00M(-2.8%)
Sep 2000
-
-$4.21M(+24.4%)
-$15.56M(-25.2%)
Jun 2000
-
-$5.56M(-113.2%)
-$12.43M(-60.5%)
Mar 2000
-
-$2.61M(+18.1%)
-$7.74M(-14.9%)
Dec 1999
-$6.74M(-49.0%)
-$3.19M(-197.1%)
-$6.74M(-76.5%)
Sep 1999
-
-$1.07M(-22.2%)
-$3.82M(-1.5%)
Jun 1999
-
-$877.00K(+45.3%)
-$3.76M(+19.5%)
Mar 1999
-
-$1.60M(-502.6%)
-$4.67M(-3.3%)
Dec 1998
-$4.52M
-$266.00K(+73.8%)
-$4.52M(-6.3%)
Sep 1998
-
-$1.01M(+43.3%)
-$4.26M(-31.3%)
Jun 1998
-
-$1.79M(-23.1%)
-$3.24M(-123.1%)
Mar 1998
-
-$1.45M
-$1.45M

FAQ

  • What is Amneal Pharmaceuticals, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. annual cash from operations year-on-year change?
  • What is Amneal Pharmaceuticals, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?
  • What is Amneal Pharmaceuticals, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Amneal Pharmaceuticals, Inc.?
  • What is Amneal Pharmaceuticals, Inc. TTM cash from operations year-on-year change?

What is Amneal Pharmaceuticals, Inc. annual cash from operations?

The current annual cash from operations of AMRX is $295.03M

What is the all-time high annual cash from operations for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high annual cash from operations is $379.00M

What is Amneal Pharmaceuticals, Inc. annual cash from operations year-on-year change?

Over the past year, AMRX annual cash from operations has changed by +$111.87M (+61.07%)

What is Amneal Pharmaceuticals, Inc. quarterly cash from operations?

The current quarterly cash from operations of AMRX is $83.82M

What is the all-time high quarterly cash from operations for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high quarterly cash from operations is $259.65M

What is Amneal Pharmaceuticals, Inc. quarterly cash from operations year-on-year change?

Over the past year, AMRX quarterly cash from operations has changed by +$44.16M (+111.36%)

What is Amneal Pharmaceuticals, Inc. TTM cash from operations?

The current TTM cash from operations of AMRX is $351.01M

What is the all-time high TTM cash from operations for Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. all-time high TTM cash from operations is $478.10M

What is Amneal Pharmaceuticals, Inc. TTM cash from operations year-on-year change?

Over the past year, AMRX TTM cash from operations has changed by +$260.97M (+289.83%)
On this page